A Canadian Economic Analysis of U.S. Oncology Adjuvant Trial 9735

Bernard, L; Verma, Shailendra; Thompson, MF; Chan, Biu; Mittmann, Nicole; Asma, L.; Se, Jones

doi:10.3747/co.v18i2.701

Cited by 6 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings of the study in America that examined the cost of metastatic breast cancer showed that the cost of treatment was 44%, the cost of palliative and supportive was 31% and lost productivity was 21% of the total cost of metastatic breast cancer (Sorensen et al, 2012). In the study of Bernard, 70% of the total costs in AC arm was related to the cost of chemotherapy (Bernard et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

“…They showed that the high cost of the PG regimen was due to the costs of chemotherapy drugs in PG regimen and the Gemcitabin on the eighth day (Chen et al, 2002). Bernard et al in 2011, Younis et al in 2011 and Liubao in separate studies showed that the low cost of the AC regimen was due to the costs of chemotherapy drugs in AC regimen (Liubao et al, 2009;Bernard et al, 2011;Younis et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran

Hatam

Askarian²,

Javan-Noghabi³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: A cost-utility analysis was performed to assess the cost-utility of neoadjuvant chemotherapy regimens containing doxorubicin and cyclophosphamide (AC) versus paclitaxel and gemcitabine (PG) for locally advanced breast cancer patients in Iran. Materials and Methods: This cross-sectional study in Namazi hospital in Shiraz, in the south of Iran covered 64 breast cancer patients. According to the random numbers, the patients were divided into two groups, 32 receiving AC and 32 PG. Costs were identified and measured from a community perspective. These items included medical and non-medical direct and indirect costs. In this study, a data collection form was used. To assess the utility of the two regimens, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (EORTC QLQ-C30) was applied. Using a decision tree, we calculated the expected costs and quality adjusted life years (QALYs) for both methods; also, the incremental cost-effectiveness ratio was assessed. Results: The results of the decision tree showed that in the AC arm, the expected cost was 39,170 US$ and the expected QALY was 3.39 and in the PG arm, the expected cost was 43,336 dollars and the expected QALY was 2.64. Sensitivity analysis showed the cost effectiveness of the AC and ICER=-5535 US$. Conclusions: Overall, the results showed that AC to be superior to PG in treatment of patients with breast cancer, being less costly and more effective.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran

Hatam

Askarian²,

Javan-Noghabi³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…[ 26 ] In previous studies, the low cost of AC regimen was due to costs of chemotherapy drugs. [ 25 27 28 ] The results of this study showed that the response to treatment in AC chemotherapy regimen with 84% was higher than PG chemotherapy regimen with 75%. In a study which conducted by Colomer et al .…”

Section: Discussionmentioning

confidence: 78%

“…showed that 70% of the total costs in AC was associated with the cost of chemotherapy. [ 25 ] Furthermore, in the Chen et al ., study 65% of total costs in PG was related to the cost of chemotherapy. [ 26 ] Chen et al .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine

et al. 2018

View full text Add to dashboard Cite

Background:A decision analysis model was developed to assess the cost-effectiveness of adriamycin and cyclophosphamide (AC) in comparison with paclitaxel and gemcitabine (PG) in women with advanced breast cancer in Iran.Materials and Methods:This is a cost-effectiveness analysis performed as a cross-sectional study in Namazi Hospital in Shiraz, Iran. Patients were divided into two groups by random numbers, 32 women in the AC group and 32 women in the PG group. The costs were measured using the societal perspective and effectiveness of 2 regimens were assessed using tumor response. By a decision tree, the incremental cost-effectiveness ratio was calculated. In addition, the robustness of results was examined by sensitivity analysis.Results:The estimated total cost of AC and PG per patient was 1565.23 ± 765.31 and 2099.08 ± 926.99, respectively. Response to treatment in AC and PG arm were 84% versus 75% respectively. The incremental cost-effectiveness ratio results showed AC is a dominate alternative.Conclusion:Overall, AC was a simple dominate strategy. In other words, AC was estimated to have a lower cost and greater effectiveness than PG.

show abstract

The cost of chemotherapy administration: a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

A Canadian Economic Analysis of U.S. Oncology Adjuvant Trial 9735

Abstract: alternative to ac in Canadian clinical practice for the adjuvant treatment of operable early breast cancer.

Cited by 6 publications

References 17 publications

Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran

Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran

The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine

The cost of chemotherapy administration: a systematic review and meta-analysis

Contact Info

Product

Resources

About